Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.

Sacubitril valsartan, a multicentric experience

Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy

Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy

Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy

Benefits of early administration of ivabradine in stabilized patients hospitalized due to worsening heart failure: insights from the Optimize Heart Failure Care Program

Series of patients treated with sacubitril-valsartan in a cardiology day clinic: efficacy and safety after 6 months of follow-up

Effects of empagliflozin on exercise capacity and LV diastolic function in HFpEF and type-2 diabetes mellitus: rationale and design of prospective intervention study

Acute Effect of Sacubitril/Valsartan on Depression Score in patients with Acute Decompansed Heart Failure on the First Day of Theraphy:A Prospective Analysis from Our Center Experiences

Titration process and predictors of achieving target dose of sacubitril/valsartan in patients with chronic heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.